Skip to main content
OpenTrials

Clinical trial condition

Paraproteinemias

Explore clinical trials studying Paraproteinemias. Study availability and eligibility vary by location and protocol.

3,002 public trials 569 recruiting studies
Refine in advanced search Browse all conditions

Paraproteinemias trial results

Active, Not Recruiting

A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."

NCT04998786

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • CHR Annecy, France
  • CH de la cote basque Bayonne, France
  • CHRU Hopital Haut Lévêque Bordeaux, France
  • CHU Caen, France
View all 21 locations
View Trial Details
Active, Not Recruiting

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

NCT04484623

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Tucson, Arizona, United States
  • GSK Investigational Site Fort Myers, Florida, United States
  • GSK Investigational Site Boston, Massachusetts, United States
  • GSK Investigational Site Kansas City, Missouri, United States
View all 122 locations
View Trial Details
Active, Not Recruiting

All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

NCT06956170

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Nagoya, Aichi-ken, Japan
  • GSK Investigational Site Kamogawa, Chiba, Japan
  • GSK Investigational Site Kashiwa, Chiba, Japan
  • GSK Investigational Site Matsuyama, Ehime, Japan
View all 13 locations
View Trial Details
Active, Not Recruiting

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

NCT05911321

Conditions
Aging, Blood Protein Disorders, Cardiovascular Diseases, +20 more
Locations
  • Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States
  • Atrium Health Wake Forest Baptist Medical Center Winston-Salem, North Carolina, United States
View Trial Details
Active, Not Recruiting

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

NCT05455320

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • The University of Arizona Cancer Center Tucson, Arizona, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Norwalk Hospital-oncology Norwalk, Connecticut, United States
  • MedStar Georgetown University Hospital Washington D.C., District of Columbia, United States
View all 216 locations
View Trial Details
Active, Not Recruiting

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

NCT04176718

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +19 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
View Trial Details

Related conditions